Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT05807880 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Neoplasms

Interventions

DRUG: The combination treatment of anlotinib, penpulimab and capecitabine.

Sponsor

Sun Yat-sen University

Collaborators

[object Object]